Quick Answer
Marker Therapeutics, Inc. reported Net Income of -$12.16 million for fiscal year 2025.
Marker Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$12.16M | -13.3% |
| 2024 | -$10.73M | -30.3% |
| 2023 | -$8.24M | +72.5% |
| 2022 | -$29.93M | +28.5% |
| 2021 | -$41.88M | -45.9% |
| 2020 | -$28.71M | -34.0% |
| 2019 | -$21.43M | +85.5% |
| 2018 | -$147.96M | -1247.3% |
| 2017 | -$10.98M | -347.3% |
| 2016 | -$2.46M | +92.8% |
| 2015 | -$34.07M | -10.3% |
| 2014 | -$30.88M | -458.2% |
| 2013 | -$5.53M | +5.6% |
| 2012 | -$5.86M | -188.7% |
| 2011 | -$2.03M | +42.6% |
| 2010 | -$3.53M | +79.6% |
| 2009 | -$17.35M | -690.0% |
| 2008 | -$2.20M | +43.6% |
| 2007 | -$3.89M | -198.3% |
| 2006 | -$1.30M | -32.3% |
| 2005 | -$985.6K | +63.3% |
| 2004 | -$2.68M | +53.6% |
| 2003 | -$5.78M | -152.9% |
| 2002 | -$2.28M | -240.0% |
| 2001 | -$672.0K | +28.2% |
| 2000 | -$935.3K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.00M | +13.4% | +50.2% |
| June 30, 2025 | -$4.02M | -83.1% | +9.7% |
| March 31, 2025 | -$4.45M | -85.8% | -92.6% |
| September 30, 2024 | -$2.31M | +22.6% | -5.3% |
| June 30, 2024 | -$2.19M | -187.2% | +8.4% |
| March 31, 2024 | -$2.39M | +51.8% | +19.8% |
| September 30, 2023 | -$2.98M | +56.9% | -218.5% |
| June 30, 2023 | $2.52M | +127.2% | +150.6% |
- Marker Therapeutics, Inc. showed a decrease of -13.3% in Net Income compared to the prior fiscal year.
- Over the 2000–2025 period, Marker Therapeutics, Inc.’s net income has declined by 1200.5% (from -$935.3 thousand to -$12.16 million).
- The most recent figure is from Marker Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: